Gustavo Paredes
Family Medicine · Coachella, CANPI 1164697173
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $66.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$666
- GSK$585
- Bayer$493
- Amgen$462
- Novo Nordisk$420
- Boehringer Ingelheim$149
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,382100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $666 |
| GSK | 11 | $585 |
| Bayer | 7 | $493 |
| Amgen | 6 | $462 |
| Novo Nordisk | 8 | $420 |
| Boehringer Ingelheim | 3 | $149 |
| Astellas Pharma US Inc | 2 | $146 |
| Si-bone, Inc. | 1 | $134 |
| Merck | 1 | $130 |
| Lilly USA, LLC | 2 | $126 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $124 |
| Sunovion Pharmaceuticals Inc. | 1 | $121 |
| Amylyx Pharmaceuticals, Inc. | 1 | $118 |
| Johnson & Johnson | 1 | $104 |
| Dynavax Technologies Corporation | 1 | $100 |
| Sanofi Pasteur Inc. | 1 | $83 |
| Pfizer | 3 | $64 |
| Merz North America, Inc. | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $29 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$337
- FARXIGA$250
- AIRSUPRA$238
- Repatha$224
- iFuse Implant$134
- PNEUMOVAX 23$130
- BREZTRI$126
- VOQUEZNA$125
- NURTEC ODT$125
- TRELEGY ELLIPTA$125
- MYRBETRIQ$124
- INJECTAFER$124
- AREXVY$122
- SHINGRIX$122
- RYBELSUS$122
- APTIOM$121
- Otezla$120
- JARDIANCE$119
- RELYVRIO$118
- Tresiba$117
How this compares
$4,382 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 205 | $244,072 |
| JanuviaSitagliptin Phosphate | 168 | $177,342 |
| OzempicSemaglutide | 146 | $149,477 |
| EliquisApixaban | 100 | $98,805 |
| TrulicityDulaglutide | 75 | $79,547 |
| FarxigaDapagliflozin Propanediol | 67 | $60,528 |
| MyrbetriqMirabegron | 65 | $50,706 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 43 | $36,823 |
| XifaxanRifaximin | 11 | $31,599 |
| MounjaroTirzepatide | 32 | $30,966 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $19,966 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $19,890 |
| BrilintaTicagrelor | 21 | $13,000 |
| Atorvastatin Calcium | 1,139 | $12,879 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 86 | $9,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $149 | $244,072205 claims |
| MerckJanuvia | $130 | $177,342168 claims |
| Novo NordiskOzempic | $420 | $149,477146 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $126 | $110,513107 claims |
| PfizerEliquis | $64 | $98,805100 claims |
| AstraZenecaFarxiga, Brilinta | $666 | $73,52888 claims |
| Astellas Pharma US IncMyrbetriq | $146 | $50,70665 claims |
| GSKTrelegy Ellipta | $585 | $19,89022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Coachella
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.